Post Content

We recently compiled a list of the 9 Most Undervalued Healthcare Stocks to Buy Now. Bio-Rad Laboratories, Inc. is among the most undervalued stocks to invest in.

TheFly reported on April 7 that Citigroup lowered its rating on BIO from Buy to Neutral and reduced its price target from $375 to $300. The revision reflected concerns that the company’s process chromatography segment is unlikely to regain strong growth or margin expansion, despite being a key driver of performance. The outlook was also weighed down by continued uncertainty in Bio-Rad’s diagnostics operations in China, adding further pressure to near-term expectations for the business.

More recently, on April 14, Bio-Rad Laboratories, Inc. (NYSE:BIO) expanded its portfolio of recombinant monoclonal anti-idiotypic antibodies by introducing multiple new highly specific antibody products targeting a range of biotherapeutic drugs, including treatments such as Evenity, Crysvita, Taltz, Empliciti, Sarclisa, Beyfortus, and Imjudo, along with a newly developed antibody for Trulicity.

Bio-Rad Laboratories, Inc. (BIO) PT Reduced to $300 by Citigroup Amid Process Chromatography Concerns
Bio-Rad Laboratories, Inc. (BIO) PT Reduced to $300 by Citigroup Amid Process Chromatography Concerns

The company also introduced its first antibody set designed to detect Fc region YTE mutations, supporting more advanced analysis of modified therapeutic antibodies. These additions are intended to improve the accuracy of pharmacokinetic and anti-drug antibody testing used in drug development and monitoring. The new offerings broaden BIO’s capabilities in supporting biologic and biosimilar research with more precise and adaptable bioanalytical tools.

Bio-Rad Laboratories, Inc. (NYSE:BIO) is a global life science company founded in 1952 and based in California. It develops and supplies tools, instruments, and diagnostics for molecular biology, protein research, and clinical laboratory testing.

While we acknowledge the potential of BIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 AI-Powered Biotech Stocks to Buy Right Now and 10 Most Undervalued Dow Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.

 

error: Content is protected !!